SCHEMBL6583331

SCHEMBL6583331

O=C(Nc1cccc(C(F)(F)F)c1)Nc1c(Cl)cc(Cl)c2ccc(O)cc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 6/20 0.61
KDR P35968 1/20 0.58
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
MAPT P10636 2/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 1/20 0.56
NTRK1 P04629 1/20 0.55
CDK19 Q9BWU1 1/20 0.55
BAZ1A Q9NRL2 1/20 0.53
ALDH1A1 P00352 2/20 0.52
GRIK1 P39086 2/20 0.51
LMNA P02545 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
TP53 P04637 1/20 0.49
GAA P10253 1/20 0.49
RXFP1 Q9HBX9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6590819 0.84 TRPV1 (0.62) TRPV1KMT2AMEN1MAPTHTT
SCHEMBL6583533 0.82 TRPV1 (0.77) TRPV1KDRCA1CA2CA9
SCHEMBL14601705 0.81 KDR (0.75) TRPV1KDRKMT2AMEN1MAPT
SCHEMBL26697304 0.81 KDR (0.74) TRPV1KDRKMT2AMEN1MAPT
SCHEMBL6586572 0.81 TRPV1 (0.64) TRPV1KDRCA1CA2CA9
SCHEMBL6376812 0.78 KMT2A (0.79) TRPV1KDRKMT2AMEN1MAPT
SCHEMBL6809756 0.78 CNR1 (0.48) TRPV1KDRKMT2AMEN1
SCHEMBL5597699 0.78 KMT2A (0.90) KDRKMT2AMEN1MAPTHTT
SCHEMBL30101230 0.78 KMT2A (0.90) KDRKMT2AMEN1MAPTHTT
SCHEMBL3692790 0.77 KDR (0.73) TRPV1KDRKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259875-A1 Amine derivatives BAYER HEALTHCARE AG (DE) 2004-12-23 US claimed
EP-1414788-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS Bayer HealthCare AG (DE) 2004-05-06 EP claimed
WO-2003014064-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-02-20 WO claimed
US-20040259875-A1 Amine derivatives BAYER HEALTHCARE AG (DE) 2004-12-23 US disclosed
EP-1414788-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS Bayer HealthCare AG (DE) 2004-05-06 EP disclosed
WO-2003014064-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259875-A1 Amine derivatives AVPR1A, GRIN1, OPRL1 TRPV1 14/4885KDR 615/4885KMT2A 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.